(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.71%) $81.35
(-1.81%) $1.955
(0.02%) $2 303.30
(-0.13%) $26.62
(-0.27%) $945.60
(0.09%) $0.938
(0.19%) $11.12
(0.08%) $0.801
(0.00%) $93.45
-2.91% $ 1.670
@ $1.840
Emitido: 14 feb 2024 @ 11:29
Retorno: -9.24%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: -1.60 %
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
Volumen de hoy | 91 979.00 |
Volumen promedio | 288 616 |
Capitalización de mercado | 32.12M |
EPS | $-0.530 ( 2024-04-04 ) |
Próxima fecha de ganancias | ( $-2.03 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.200 |
ATR14 | $0.00600 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jin David | Buy | 2 352 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 22 705 545 | Sell: 91 742 |
Volumen Correlación
Fortress Biotech Inc Correlación
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fortress Biotech Inc Correlación - Moneda/Commodity
Fortress Biotech Inc Finanzas
Annual | 2023 |
Ingresos: | $84.51M |
Beneficio Bruto: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
Ingresos: | $84.51M |
Beneficio Bruto: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
Ingresos: | $75.74M |
Beneficio Bruto: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
Ingresos: | $63.13M |
Beneficio Bruto: | $31.05M (49.18 %) |
EPS: | $-0.800 |
Financial Reports:
No articles found.
Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico